Serpinb5, referred to as Maspin (mammary serine protease inhibitor), was identified as a serine protease inhibitor and recognized as a tumor suppressor, and its loss has been observed in breast and prostate cancers, making it a promising diagnostic marker for monitoring tumor progression [35,36]. Here, SERPINB5 is linked to neoplasm.